About
Yusuf Erkul is co-founder and CEO of Kernal Biologics, a biotech company focused on messenger RNA immunotherapy. He previously worked at Merck on oncology drug discovery and development, holds an M.D. from Hacettepe University, a B.S. in Biology from MIT, and an executive MBA from MIT Sloan.
Yusuf Erkul @yusuf_erkul
We’re proud to welcome another exceptional partner to our growing list of supporters! With backing from @Amgen, @nvidia , @EliLillyandCo, and now @ARPA_H), we’re strongly positioned to deliver transformative impact for patients worldwide. https://t.co/muioI96maG
Oct 7, 2025 · ♥ 1
Yusuf Erkul @yusuf_erkul
We’re proud to have Lilly’s support as we accelerate the future of in vivo cell therapies! https://t.co/w3yxhnPGV8
Oct 3, 2025
Yusuf Erkul @yusuf_erkul
We're excited to share recent data on our mRNA2.0 pipeline at SITC. KR-336 unlocks the full potential of #oncoselective mRNAs in immuno-oncology with #peripheral LNPs. https://t.co/0FjJEH74oc
Oct 31, 2023 · ♥ 10
Founder at Kernal BiologicsYC S20
Intro paths
Yusuf went through Y Combinator (Summer 2020) — any YC alum in your network can reach them through the YC community.
Their group partner at YC was Jared Friedman, General Partner at Y Combinator — the partner who ran Kernal Biologics's batch and knows the company first-hand. YC profile ↗
In turn, Yusuf can intro founders to Kernal Biologics's investors below.
Kernal Biologics's investors · 7
Co-founders at Kernal Biologics
